Shijing Luo Ph.D. (Nora)

Nora Luo focuses on patent prosecution and strategic intellectual property counseling in the biotechnology and pharmaceutical industries. Her practice includes IP due diligence evaluations in connection with public and private financings and transactions (including cross-border transactions), supporting IP transactions, freedom-to-operate analyses, patentability evaluations, preparation and prosecution of patent applications, patent portfolio management, and supporting Patent Trial and Appeal Board (PTAB) proceedings and other IP litigations.

Nora has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapy (for example, antibodies, antibody drug conjugates [ADCs], peptide conjugates, vaccines, cell-based therapies, CAR-T and CAR-NK cell technology, immune checkpoint modulators), gene therapy, CRISPR technology, siRNA therapeutics, mRNA delivery, mRNA-based therapy, lipid nanoparticles, viral vector-based gene delivery system (for example, AAV), antibody engineering, RNA splicing, cancer therapeutics, virology, stem cells, neurological disorder therapeutics, high-throughput screening, genomics, diagnostic assays, anti-aging therapeutics, AI-developed therapeutics, and small molecule pharmaceuticals.

Nora holds a Ph.D. in molecular biology from Princeton University. While at Princeton, she was awarded the American Society for Cell Biology Norton B. Gilula Award and was the recipient of the National Institute of Health Fellowship. Prior to joining Jones Day, Nora was a Damon Runyon Cancer Research fellow at The Rockefeller University. Her scientific work has been published in a number of peer-reviewed journals, including Cell and Science, and was featured in The New York Times and Nature.